Hepalatide - Shanghai HEP Pharmaceutical
Alternative Names: L 47Latest Information Update: 06 Jan 2026
At a glance
- Originator Shanghai HEP Pharmaceutical
- Class Antihyperglycaemics; Antivirals; Peptides
- Mechanism of Action Sodium-bile acid cotransporter modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hepatitis B; Hepatitis D
- No development reported Diabetes mellitus
Most Recent Events
- 30 Dec 2025 Shanghai HEP Pharmaceutical plans a phase-III trial for Hepatitis D in China (SC), (NCT07309380)
- 07 Nov 2025 Efficacy data from a phase II trial in Hepatitis B presented at the The Liver Meeting 2025: 76th Annual Meeting of the American Association for the Study of Liver Diseases 2025 (AASLD-2025)
- 07 Nov 2025 Efficacy and adverse events data from a phase II trial in Hepatitis B presented at the 76th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2025)